A leading national expert and researcher in personalized medicine, Dr. Shuldiner focuses on the genetics of age-related diseases, including type 2 diabetes, obesity, osteoporosis, and cardiovascular disease. He is best known for his studies involving Old Order Amish, a homogeneous population ideal for genetic studies. In his part-time faculty role, he serves as director of the University of Maryland School of Medicine’s Personalized and Genomic Medicine Program, and leads a multidisciplinary research team that uses state-of-the-art molecular, genetic, statistical, and epidemiological methods. His group reported the first null mutation in the APOC3 gene and its association with low blood triglyceride levels and cardioprotection, which validates treatment for hypertriglyceridemia (elevated triglyceride levels). Most recently, his group identified a common gene variant that reduces the benefit of clopidogrel (a blood thinner used to help prevent stroke, heart attacks and other health problems), which many cardiologists now use to individualize anti-platelet therapy. Dr. Shuldiner also serves as vice president and co-head of the Regeneron Genetics Center, a program that focuses on early gene discovery and functional genomics and facilitates drug development. Dr. Shuldiner has authored more than 300 original articles in leading journals as well as 78 reviews and book chapters. Additionally, he is the recipient of a number of awards. He serves on several steering and advisory committees related to his expertise in complex disease genetics and the translation of genetic discoveries to the clinical setting.